Literature DB >> 25505335

Antibody-derived in vivo imaging of tau pathology.

Senthilkumar Krishnaswamy1, Yan Lin1, Wajitha J Rajamohamedsait1, Hameetha B Rajamohamedsait1, Pavan Krishnamurthy1, Einar M Sigurdsson2.   

Abstract

Antibodies or their derivatives as imaging probes for pathological tau protein have great potential, but have not been well studied. In particular, smaller, single-chain-variable antibody fragments (scFv's) are attractive for detecting tau lesions in live subjects. Here, we generated libraries of scFv's and identified numerous phospho-tau-selective scFv's. Peripheral injection of one of these scFv's consistently resulted in a strong in vivo brain signal in transgenic tauopathy mice, but not in wild-type or amyloid-β plaque mice. The parent tau antibody provided similar results, albeit with a weaker signal intensity. The imaging signal correlated very well with colocalization of the probe with intraneuronal tau aggregates. Both were associated with markers of endosomes, autophagosomes, and lysosomes, suggesting their interaction in these degradation pathways. Such specific antibody-derived imaging probes have great potential as diagnostic markers for Alzheimer's disease and related tauopathies.
Copyright © 2014 the authors 0270-6474/14/3416835-16$15.00/0.

Entities:  

Keywords:  Alzheimer's disease; IVIS; diagnosis; imaging; scFv; tau

Mesh:

Substances:

Year:  2014        PMID: 25505335      PMCID: PMC4261104          DOI: 10.1523/JNEUROSCI.2755-14.2014

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  43 in total

Review 1.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

2.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

Authors:  Nobuyuki Okamura; Shozo Furumoto; Michelle T Fodero-Tavoletti; Rachel S Mulligan; Ryuichi Harada; Paul Yates; Svetlana Pejoska; Yukitsuka Kudo; Colin L Masters; Kazuhiko Yanai; Christopher C Rowe; Victor L Villemagne
Journal:  Brain       Date:  2014-03-27       Impact factor: 13.501

3.  Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease.

Authors:  Nobuyuki Okamura; Takahiro Suemoto; Shozo Furumoto; Masako Suzuki; Hiroshi Shimadzu; Hiroyasu Akatsu; Takayuki Yamamoto; Hironori Fujiwara; Miyako Nemoto; Masahiro Maruyama; Hiroyuki Arai; Kazuhiko Yanai; Tohru Sawada; Yukitsuka Kudo
Journal:  J Neurosci       Date:  2005-11-23       Impact factor: 6.167

4.  Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.

Authors:  Jiaping Gu; Erin E Congdon; Einar M Sigurdsson
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

5.  Cloning antifungal single chain fragment variable antibodies by phage display and competitive panning elution.

Authors:  Senthilkumar Krishnaswamy; M Enamul Kabir; Masahiko Miyamoto; Yasuhiro Furuichi; Tadazumi Komiyama
Journal:  Anal Biochem       Date:  2009-08-07       Impact factor: 3.365

Review 6.  Harnessing the immune system for treatment and detection of tau pathology.

Authors:  Erin E Congdon; Senthilkumar Krishnaswamy; Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

7.  Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.

Authors:  Diana L Castillo-Carranza; Julia E Gerson; Urmi Sengupta; Marcos J Guerrero-Muñoz; Cristian A Lasagna-Reeves; Rakez Kayed
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 8.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

9.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808.

Authors:  David T Chien; A Katrin Szardenings; Shadfar Bahri; Joseph C Walsh; Fanrong Mu; Chunfang Xia; William R Shankle; Alan J Lerner; Min-Ying Su; Arkadij Elizarov; Hartmuth C Kolb
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

10.  Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.

Authors:  Michelle T Fodero-Tavoletti; Shozo Furumoto; Leanne Taylor; Catriona A McLean; Rachel S Mulligan; Ian Birchall; Ryuichi Harada; Colin L Masters; Kazuhiko Yanai; Yukitsuka Kudo; Christopher C Rowe; Nobuyuki Okamura; Victor L Villemagne
Journal:  Alzheimers Res Ther       Date:  2014-02-26       Impact factor: 6.982

View more
  26 in total

Review 1.  Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models.

Authors:  Senthilkumar Krishnaswamy; Huai-Wei Huang; Isabella S Marchal; Hyung Don Ryoo; Einar M Sigurdsson
Journal:  Neurobiol Dis       Date:  2020-01-23       Impact factor: 5.996

2.  Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau.

Authors:  Dan Li; Lei Wang; Brandon F Maziuk; Xudong Yao; Benjamin Wolozin; Yong Ku Cho
Journal:  J Biol Chem       Date:  2018-06-13       Impact factor: 5.157

3.  Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach.

Authors:  Dov B Shamir; Nina Rosenqvist; Suhail Rasool; Jan T Pedersen; Einar M Sigurdsson
Journal:  Alzheimers Dement       Date:  2016-03-23       Impact factor: 21.566

4.  Structural characterization of monoclonal antibodies targeting C-terminal Ser404 region of phosphorylated tau protein.

Authors:  Jessica E Chukwu; Erin E Congdon; Einar M Sigurdsson; Xiang-Peng Kong
Journal:  MAbs       Date:  2019-02-26       Impact factor: 5.857

Review 5.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 6.  Tau-targeting therapies for Alzheimer disease.

Authors:  Erin E Congdon; Einar M Sigurdsson
Journal:  Nat Rev Neurol       Date:  2018-07       Impact factor: 42.937

Review 7.  Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 8.  Tau Immunotherapy.

Authors:  Einar M Sigurdsson
Journal:  Neurodegener Dis       Date:  2015-11-10       Impact factor: 2.977

9.  Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders.

Authors:  Brian Spencer; Sven Brüschweiler; Marco Sealey-Cardona; Edward Rockenstein; Anthony Adame; Jazmin Florio; Michael Mante; Ivy Trinh; Robert A Rissman; Robert Konrat; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2018-06-14       Impact factor: 17.088

Review 10.  Current Status of Clinical Trials on Tau Immunotherapies.

Authors:  Changyi Ji; Einar M Sigurdsson
Journal:  Drugs       Date:  2021-06-08       Impact factor: 11.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.